You can buy or sell Stemline and other stocks, options, ETFs, and crypto commission-free!
Stemline Therapeutics, Inc. Common Stock, also called Stemline, is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Read More Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock
Stemline Therapeutics Inc (NASDAQ: STML) reported a wider first-quarter net loss per share Friday, dragged by higher R&D expenses, which nearly tripled from a year ago.
Seeking AlphaMay 10
Stemline Therapeutics' CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript
Stemline Therapeutics, Inc (NASDAQ:STML) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Ken Hoberman – Chief Operating Officer Ivan Bergstein – Chief Executive Officer Robert Francomano – Senior Vice President Global Head of Commercial David Gionco – Chief Accounting Officer Conference Call Participants Jessica Fye – JP Morgan Boris Peaker – Cowen Matt Kaplan – Ladenburg Thalmann Ram Selvaraju – Wainwright Joe Catanzaro – Piper Jaffray Jotin Marango – Roth Capital ...
-$0.63 per share
-$0.73 per share